Born 1974

Johan Liwing has over 15 years of experience in senior positions within the pharmaceutical industry, including serving as CEO of the biotech company XNK Therapeutics and holding senior roles within the Johnson & Johnson group, both in Sweden and internationally. He holds a Master of Science degree in Engineering Physics from the Royal Institute of Technology (KTH). Johan Liwing has been CEO since December 2024.

Other assignments: CEO of Prosmedic Sweden.

Direct and/or indirect shareholdings: 453,000.

Direct and/or indirect holdings of warrants: 3,600,000 warrants 2025/2028.

Born in 1970.

Hugo Petit holds a Master's degree in Organizational and Behavioral Sciences from the Netherlands Defence Academy in Breda, as well as an MBA in Executive Management from Uppsala University. He has 18 years of experience from various CFO roles in both listed and privately held growth companies, primarily within the life science sector. Hugo Petit has been CFO since April 2023.

Other positions: CFO at Energiengagemang i Sverige AB and CFO at Zwipe AS. Board member at Abilia Holding AB, Catator AB, and Petit Consulting AB.

Direct and/or indirect shareholdings: 1,140,000.

Direct and/or indirect holdings of warrants: 789,000 warrants 2023/2027 & 800,000 warrants 2025/2028.

Born in 1971.

Staffan Rosenborg has over 25 years of experience in clinical drug development and clinical trials. He is a specialist physician in clinical pharmacology and nephrology and an Associate Professor at Karolinska Institutet. Staffan Rosenborg has served as CMO on a consultancy basis since July 2021, alongside his position as Head of Clinical Trials in Clinical Pharmacology at Karolinska University Hospital.

Other positions: Head of Clinical Trials in Clinical Pharmacology at Karolinska University Hospital.

Direct and/or indirect shareholdings: 0.

Direct and/or indirect holdings of warrants: 0.

Born in 1988.

Isabelle Morin has over 10 years of experience in clinical drug development and clinical trials. Most recently, she held a senior role at LINK Medical Research. She holds a Master's degree in Biomedicine from Uppsala University. Isabelle Morin has been HoCO since June 2024.

Other positions: None.

Direct and/or indirect shareholdings: 355,000.

Direct and/or indirect holdings of warrants: 692,000 warrants 2023/2027 & 840,000 warrants 2025/2028.

Born in 1966.

Björn Eriksson has more than 20 years of experience in project management within drug development. He has, among other roles, worked with drug development at Amplifier Therapeutics (formerly Betagenon). He holds a PhD in Molecular Biology from Umeå University. Björn Eriksson has been CSO since August 2025.

Other positions: None.

Direct and/or indirect shareholdings: 15,200.

Direct and/or indirect holdings of warrants: 263,572 warrants 2023/2027.

Born in 1967.

Ingela Bergqvist has worked in clinical drug development for nearly 20 years. She holds a PhD in Cell and Molecular Biology from Umeå University. Ingela Bergqvist has been HoPR since August 2025.

Other positions: None.

Direct and/or indirect shareholdings: 0.

Direct and/or indirect holdings of warrants: 125,000 warrants 2023/2027.

Born in 1964.

Erik Lund has over 30 years of experience in research and business development, including roles at UT Southwestern in Dallas, USA; Merck/MSD in the USA and Sweden; as well as working as an independent business development consultant in the pharmaceutical industry. He holds an MSc in Chemical Engineering from the Royal Institute of Technology (KTH) and a PhD in Medicine from Karolinska Institutet. Erik Lund has served as BDO on a consultancy basis since January 2025.

Other positions: CEO of Ytterby Life Science AB; Principal of Cordator Life Science AB.

Direct and/or indirect shareholdings: 0.

Direct and/or indirect holdings of warrants: 0.